SEC Comment Letter for PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Mar 1, 2012
PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: March 1, 2012 · CIK: 0001157075 · Accession: 0000000000-12-010929
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-68008
Letter
March 1, 2012 Via E-mail Robert F. Ryan President and Chief Executive Officer Nuvilex, Inc. 12510 Prosperity Drive, Suite #310 Silver Spring, MD 20904
Re: Nuvilex, Inc. Item 4.01 Form 8-K Filed February 15, 2012 File No. 333-68008
Dear Mr. Ryan: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Joel Parker Joel Parker Accounting Branch Chief
Show Raw Text
March 1, 2012 Via E-mail Robert F. Ryan President and Chief Executive Officer Nuvilex, Inc. 12510 Prosperity Drive, Suite #310 Silver Spring, MD 20904 Re: Nuvilex, Inc. Item 4.01 Form 8-K Filed February 15, 2012 File No. 333-68008 Dear Mr. Ryan: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Joel Parker Joel Parker Accounting Branch Chief